Evolving role of early antifungals in the adult intensive care unit

Critical Care Medicine

Volumn 37, Issue 5, 2009, Pages 1580-1593

  Lam, Simon W ^a   Eschenauer, Gregory A ^b   Carver, Peggy L ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antifungals; Candida; Empiric therapy; Fluconazole; Intensive care unit; Prophylaxis

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; FLUCONAZOLE; KETOCONAZOLE; NYSTATIN; PLACEBO;

ABDOMINAL CANDIDIASIS; ALGORITHM; CANDIDA; CANDIDAL PERITONITIS; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRITICALLY ILL PATIENT; DRUG MEGADOSE; FUNGAL COLONIZATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE;

ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS; CROSS INFECTION; FEMALE; FLUCONAZOLE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67650486325     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819dec9b     Document Type: Article

References (74)

1. Gudlaugsson O, Gillespie S, Lee K, et al: Attributable mortality of nosocomial candi-demia, revisited. Clin Infect Dis 2003; 37: 1172-1177
2. Morgan J, Meltzer MI, Plikaytis BD, et al: Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26:540-547
3. Wey SB, Mori M, Pfaller MA, et al: Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149:2349-2353
4. Wisplinghoff H, Bischoff T, Tallent SM, et al: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317
5. Zaoutis TE, Argon J, Chu J, et al: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005; 41:1232-1239
6. Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32:1191-1200
7. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-3645
8. Alexander BD, Ashley ED, Reller LB, et al: Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 2006; 54:277-282
9. Kedzierska A, Kochan P, Pietrzyk A, et al: Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: Galactoman-nan, mannan and (1->3)-beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis 2007; 26:755-766
10. Garey KW, Neuhauser MM, Bearden DT, et al: Evaluation of antifungals in the surgical intensive care unit: A multi-institutional study. Mycoses 2006; 49:226-231
11. Kanafani ZA, Perfect JR: Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact. Clin Infect Dis 2008; 46:120-128
12. Kontoyiannis DP, Lewis RE: Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359:1135-1144
13. Saad AH, DePestel DD, Carver PL: Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744
14. Yu DT, Peterson JF, Seger DL, et al: Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 2005; 14:755-767
15. McKinnon PS, Goff DA, Kern JW, et al: Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136:1401-1408; discussion 1409
16. Lipsett PA: Surgical critical care: Fungal in- fections in surgical patients. Crit Care Med 2006; 34(Suppl 9):S215-S224
17. Charles PE, Dalle F, Aube H, et al: Candida spp. colonization significance in critically ill medical patients: A prospective study. Intensive Care Med 2005; 31:393-400
18. Agvald-Ohman C, Klingspor L, Hjelmqvist H, et al: Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 2008; 40:145-153
19. Blumberg HM, Jarvis WR, Soucie JM, et al: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-186
20. Bross J, Talbot GH, Maislin G, et al: Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am J Med 1989; 87:614-620
21. Craven DE, Kunches LM, Lichtenberg DA, et al: Nosocomial infection and fatality in medical and surgical intensive care unit patients. Arch Intern Med 1988; 148:1161-1168
22. Eggimann P, Garbino J, Pittet D: Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3:772-785
23. Jorda-Marcos R, Alvarez-Lerma F, Jurado M, et al: Risk factors for candidaemia in critically ill patients: A prospective surveillance study. Mycoses 2007; 50:302-310
24. Leon C, Ruiz-Santana S, Saavedra P, et al: A bedside scoring system ("Candida score") for early antifungal treatment in nonneutro-penic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-737
25. Michalopoulos AS, Geroulanos S, Mentzelo-poulos SD: Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 2003; 124:2244-2255
26. Paphitou NI, Ostrosky-Zeichner L, Rex JH: Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: Approach to developing practical criteria for systematic use in anti-fungal prophylaxis trials. Med Mycol 2005; 43:235-243
27. Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, et al: Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect 2004; 10: 550-555
28. Petri MG, Konig J, Moecke HP, et al: Epidemiology of invasive mycosis in ICU patients: A prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 1997; 23:317-325
29. Pittet D, Monod M, Suter PM, et al: Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220:751-758
30. Ostrosky-Zeichner L, Sable C, Sobel J, et al: Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-276
31. Piarroux R, Grenouillet F, Balvay P, et al: Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-2449
32. Vincent JL, Anaissie E, Bruining H, et al: Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24:206-216
33. Dupont H, Bourichon A, Paugam-Burtz C, et al: Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003; 31:752-757
34. Normand S, Francois B, Darde ML, et al: Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Med 2005; 31:1508-1513
35. Silvestri L, van Saene HK, Milanese M, et al: Impact of selective decontamination of the digestive tract on fungal carriage and infection: Systematic review of randomized controlled trials. Intensive Care Med 2005; 31: 898-910
36. Garbino J, Lew DP, Romand JA, et al: Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-1717
37. Pelz RK, Hendrix CW, Swoboda SM, et al: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-548
38. Swoboda SM, Merz WG, Lipsetta PA: Candi-demia: The impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect (Larchmt) 2003; 4:345-354
39. Eggimann P, Francioli P, Bille J, et al: Flu-conazole prophylaxis prevents intra-abdomi-nal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-1072
40. Grewe M, Tsiotos GG, Luque de-Leon E, et al: Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg 1999; 188: 408-414
41. De Waele JJ, Vogelaers D, Blot S, et al: Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003; 37:208-213
42. Cruciani M, de Lalla F, Mengoli C: Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: A systematic review and meta-analysis. Intensive Care Med 2005; 31:1479-1487
43. Playford EG, Webster AC, Sorrell TC, et al: Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: Systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57:628-638
44. Playford EG, Webster AC, Sorrell TC, et al: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006: CD004920
45. Shorr AF, Chung K, Jackson WL, et al: Flu-conazole prophylaxis in critically ill surgical patients: A meta-analysis. Crit Care Med 2005; 33:1928-1935; Quiz 1936
46. Vardakas KZ, Samonis G, Michalopoulos A, et al: Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006; 34: 1216-1224
47. Singh N: Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003; 17:113-134, viii
48. Solomkin JS, Mazuski JE, Baron EJ, et al: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005
49. Jacobs S, Price Evans DA, Tariq M, et al: Fluconazole improves survival in septic shock: A randomized double-blind prospective study. Crit Care Med 2003; 31: 1938-1946
50. Golan Y, Wolf MP, Pauker SG, et al: Empirical anti-Candida therapy among selected patients in the intensive care unit: A cost-effectiveness analysis. Ann Intern Med 2005; 143:857-869
51. Schuster MG, Edwards JE Jr, Sobel JD, et al: Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med 2008; 149:83-90
52. Blot SI, Vandewoude KH, De Waele JJ: Candida peritonitis. Curr Opin Crit Care 2007; 13:195-199
53. Prasad N, Gupta A: Fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2005; 25:207-222
54. Sungkanuparph S, Vibhagool A, Prachark-tam R: Spontaneous cryptococcal peritonitis in cirrhotic patients. J Postgrad Med 2002; 48:201-202
55. Nair S, Kumar KS, Sachan P, et al: Spontaneous fungal peritonitis (Candida glabrata) in a patient with cirrhosis. J Clin Gastroenterol 2001; 32:362-364
56. Cleophas V, George V, Mathew M, et al: Spontaneous fungal peritonitis in patients with hepatitis B virus-related liver disease. J Clin Gastroenterol 2000; 31:77-79
57. Choi SH, Soo Kim Y, Chung JW, et al: Clinical significance of untreated Candida species isolated from ascites in cirrhotic patients. Scand J Infect Dis 2004; 36: 649-655
58. Sawyer RG, Rosenlof LK, Adams RB, et al: Peritonitis into the 1990s: Changing pathogens and changing strategies in the critically ill. Am Surg 1992; 58:82-87
59. Sotto A, Lefrant JY, Fabbro-Peray P, et al: Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002; 50:569-576
60. Calandra T, Bille J, Schneider R, et al: Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437-1440
61. Montravers P, Dupont H, Gauzit R, et al: Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34:646-652
62. Pappas PG, Rex JH, Sobel JD, et al: Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189
63. Sandven P, Qvist H, Skovlund E, et al: Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30:541-547
64. Mazuski JE, Sawyer RG, Nathens AB, et al: The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdom-inal infections: Evidence for the recommendations. Surg Infect (Larchmt) 2002; 3:175-233
65. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20:133-163
66. Pfaller MA, Messer SA, Boyken L, et al: Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: A global assessment from the ARTEMIS Anti-fungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-3146
67. Pfaller MA, Diekema DJ, Sheehan DJ: Interpretive breakpoints for fluconazole and Candida revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19:435-447
68. Nucci M, Colombo AL: Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002; 21:209-211
69. Borzotta AP, Beardsley K: Candida infections in critically ill trauma patients: A retrospective case-control study. Arch Surg 1999; 134: 657-664; discussion 664-665
70. Slotman GJ, Burchard KW: Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122:147-151
71. Savino JA, Agarwal N, Wry P, et al: Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontrans-plant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36:20-25; discussion 25-26
72. Ables AZ, Blumer NA, Valainis GT, et al: Flu-conazole prophylaxis of severe Candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000; 9:169-175
73. Ascioglu S, Rex JH, de Pauw B, et al: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34:7-14
74. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874